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Although several types of somatic cells have been reprogrammed into induced pluripotent stem cells (iPSCs) and 
then differentiated to hepatocyte-like cells (iHeps), the method for generating such cells from renal tubular epithelial 
cells shed in human urine and transplanting them into animal livers has not been described systematically. We report 
reprogramming of human urinary epithelial cells into iPSCs and subsequent hepatic differentiation, followed by a 
detailed characterization of the newly generated iHeps. The epithelial cells were reprogrammed into iPSCs by deliv-
ering the pluripotency factors OCT3/4, SOX2, KLF4, and MYC using methods that do not involve transgene inte-
gration, such as nucleofection of episomal (oriP/EBNA-1) plasmids or infection with recombinant Sendai viruses. 
After characterization of stable iPSC lines, a three-step differentiation toward hepatocytes was performed. The iHeps 
expressed a large number of hepatocyte-preferred genes, including nuclear receptors that regulate genes involved 
in cholesterol homeostasis, bile acid transport, and detoxification. MicroRNA profile of the iHeps largely paralleled 
that of primary human hepatocytes. The iHeps engrafted into the livers of Scid mice transgenic for mutant human 
SERPINA1 after intrasplenic injection. Thus, urine is a readily available source for generating human iHeps that 
could be potentially useful for disease modeling, pharmacological development, and regenerative medicine.
Key words: Urinary epithelial cells; Induced pluripotent stem cells (iPSCs); Differentiation; 
Hepatocytes
INTRODUCTION
Directed differentiation of pluripotent stem cells into 
chosen cell lineages offers great promises for disease 
modeling, drug discovery, and evaluation, as well as cell-
based therapies of various diseases (6,10). Advances in 
generating human induced pluripotent stem cells (iPSCs) 
from somatic cells by transient expression of reprogram-
ming factors have provided new opportunities to generate 
patient-specific cell types of various lineages (5,19,24,29). 
Many different types of somatic cells have been used for 
reprogramming into iPSCs. Skin fibroblasts are most com-
monly used for this purpose, but keratinocytes, periph-
eral blood cells, adipose-derived stem cells (ADSCs), 
amniotic cells, and cord blood endothelial cells have 
been also used as the starting cells (1,8,13,14,23,25,26). 
As isolating such somatic cells involves minimally inva-
sive procedures, investigators explored other sources for 
somatic cells that can be accessed noninvasively.
Recently, Zhou et al. successfully reprogrammed epi-
thelial cells shed in the urine into iPSCs (30). Evaluation 
of marker proteins indicated that these cells are exfoliated 
tubular epithelial cells. Normally, approximately 2,000 
to 7,000 cells are detached from the human renal tubular 
system and shed daily in the urine (31). The cell culture 
technique is simple and has been used successfully in sub-
jects of all ages and both genders. The round and elongated 
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cell types that emerge after culturing the cells are similar 
in gene expression profile (16,30,31). These observations 
make these cells attractive for reprogramming into iPSCs.
We used a modification of our previously reported pro-
tocol to differentiate the iPSCs sequentially to definitive 
endoderm (DE), hepatic progenitor cells, and finally to 
hepatocyte-like cells (iHeps) (2). The iHeps exhibited the 
polygonal morphology characteristic of human hepato-
cytes, including the presence of two nuclei in some of the 
cells (3,9,21). In addition, the iHeps expressed hepatocyte- 
preferred genes and miRNAs to various extents and 
exhibited several hepatocyte-specific functions, such as 
glycogen storage, indocyanin green uptake, urea synthe-
sis, and albumin secretion.
To our knowledge, this is the first detailed character-
ization of iHeps originating from renal tubular epithelial 
cells, isolated from human urine.
MATERIALS AND METHODS
Collection and Cultivation of Urinary Epithelial Cells
The urinary epithelial cells were collected and cultured 
as previously described (30,31). Briefly, 250–500 ml of 
freshly donated, midstream urine was collected in sterile 
containers, and the cells were pelleted by centrifuged at 
400 ´ g for 10 min. The pellet was washed by resuspending 
in 10 ml of cold phosphate-buffered saline (PBS; Lonza, 
Passaic, NJ, USA). After another centrifugation at 400 ´  g 
for 10 min, the pellet was resuspended in 1 ml of urinary 
cell medium (UCM) consisting of Dulbecco’s modified 
Eagle’s medium/Ham’s F12 culture medium (DMEM/F12; 
Lonza) supplemented with 10% fetal bovine serum (FBS; 
PAA-GE Healthcare Life Sciences, Marlborough, MA, 
USA), 0.1 mM nonessential amino acids (NEAA; Sigma-
Aldrich, St. Louis, MO, USA), 0.1 mM b-mercaptoethanol, 
1 mM GlutaMAX (Life Technologies, Guilford, CT, USA), 
and SingleQuot Kit CC-4127 REGM (Lonza). The cell sus-
pension was transferred to a single well of a 12-well plate, 
precoated with ultrapure water containing 0.1% gelatin 
(Millipore, Bedford, MA, USA) for 30 min. Cells were incu-
bated at 37°C, in a 4% CO2/air for 24 h. For the first 3 days, 
1 ml of fresh UCM was added daily. On day 4, 3 ml of the 
media was aspirated, and 1 ml of fresh UCM was added. 
Half of the media was replaced with fresh media every 
day until first cell colonies appeared. At a cell confluence 
of 80%–90%, the cells were released by incubation with 
trypsin/ethylenediaminetetraacetic acid (EDTA; Lonza) for 
2 min. The reaction was stopped by adding defined trypsin 
inhibitor (DTI; Gibco, Gaithersburg, MD, USA).
Generation and Cultivation of Human iPSCs
The human urinary epithelial cells were reprogrammed 
by nucleofection of episomal expression vectors pCXLE-
hOCT3/4-shp53-F (27077), pCXLE-hSK (27078), and 
pCXLE-hUL (27080) (Addgene, Cambridge, MA, USA) 
using the Amaxa Basic Nucleofector Kit for primary mam-
malian epithelial cells (VPI-1005; Lonza) as described by 
Okita et al. (15). Briefly, 1 ´  106 urinary cells were resus-
pended in 100 µl of supplemented nucleofector solution. 
One microgram of each episomal expression vector was 
added to the cell suspension and immediately transferred 
into a cuvette to run the nucleofection program T-013 of 
the nucleofector device (Lonza). After nucleofection, the 
cells were resuspended in 500 µl of UCM and transferred 
onto two wells of a Matrigel (BD Biosciences, San Diego, 
CA, USA)-coated six-well plate (Thermo Fisher Scientific, 
Waltham, MA, USA).
Our second strategy for reprogramming urinary epi-
thelial cells was based on transferring the four Yamanaka 
reprogramming factors [octamer-binding transcription 
factor 4 (Oct3/4), sex-determining region Y (SRY)-box 2 
(Sox2), Kruppel-like factor 4 (Klf4), and v-myc avian 
myelocytomatosis viral oncogene homolog (c-Myc)] 
using replication-defective recombinant Sendai viral vec-
tors (CytoTune-iPS Reprogramming Kit; No. A13780-01; 
Invitrogen, Thermo Fisher Scientific). One million uri-
nary epithelial cells were plated on two wells of a six-well 
plate. On day 1, the four kit components were added to 
1 ml of UCM and transferred to one well containing the 
urinary epithelial cells. The next day, the medium was 
replaced with fresh UCM. The cells were cultured for 
the next 6 days, changing the medium every other day 
with UCM, before replating onto a six-well plate pre-
coated with Matrigel (BD Biosciences). After 24 h, the 
UCM was changed to mTeSR iPSC medium (Stem Cell 
Technologies, Cambridge, MA, USA). Both plates were 
observed every day for the emergence of characteristic 
cell clumps or colonies. The colonies were counted 12 
to 28 days after transduction. iPSCs were harvested and 
maintained on Matrigel-coated plates in mTeSR cell cul-
ture medium and dissociated with 1 U/ml of dispase (Stem 
Cell Technologies) into small clusters and subcultured 
every 4 to 6 days.
Characterization of Human iPSCs
Expression of Oct3/4, Nanog, TRA-1-60, and SSEA4 
was verified by immunofluorescence staining using cor-
responding antibodies (Table 1). To evaluate spontaneous 
differentiation to the three germ layers in vivo, 1 ´  106 iPSCs 
were injected subcutaneously into the neck of immunode-
ficient NOD/Scid mice (Jackson Laboratory, Bar Harbor, 
ME, USA) or beneath the kidney capsule as described 
(http://www.stembook.org/node/723). Tumors appeared 
in 8 to 10 weeks after injection. After excision, the tumors 
were fixed, embedded in paraffin, and sections were stained 
with hematoxylin and eosin (H&E; Sigma-Aldrich). All 
animal experiments were performed with the approval of 
the Institutional Animal Care and Use Committee (IACUC) 
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of Albert Einstein College of Medicine and were within the 
guidelines for humane care of laboratory animals of Albert 
Einstein College of Medicine.
Karyotyping
The iPSCs, grown in Matrigel-coated dishes, were 
synchronized using 0.1 µg/ml of Colcemid solution 
(Invitrogen). After fixation with fresh methyl alcohol/gla-
cial acetic acid (3:1; Sigma-Aldrich), a small quantity of 
the cells was spread onto 10 slides. Chromosomes were 
examined, counted by phase-contrast microscopy, and 
photographed (200×).
Differentiation of Human Urinary Epithelial  
Cell-Derived iPSCs Into iHeps
Stepwise-directed differentiation of the iPSCs into 
iHeps was achieved by a modification of the method 
reported previously (2). Briefly, 1 to 5 × 104 UiPSCs at a 
passage number of 20–30 were plated onto six-well plates 
precoated with Matrigel (BD Biosciences). The next day, 
UiPSCs were seen as small colonies with ~60% confluence. 
The medium was changed to DMEM/F12 enriched with 
100 ng/ml recombinant Activin A (PeproTech, Rocky Hill, 
NJ, USA), 100 ng/ml fibroblast growth factor-2 (FGF2; 
PeproTech) plus 50 ng/ml recombinant human Wnt3a 
(R&D Systems, Minneapolis, MN, USA) and was main-
tained for the next 3 days. Concentrations of KnockOut 
SR Xenofree medium (KSR; Life Technologies) was 0%, 
0.2%, and 2.0% for the first, second, and final 24 h, respec-
tively. For the next 8 days, cells were cultivated in DMEM/
F12 supplemented with 10% KSR, 1 mM NEAA, 1 mM 
L-glutamine, 1% dimethyl sulfoxide (DMSO; Sigma-
Aldrich), and 100 ng/ml hepatocyte growth factor (HGF; 
PeproTech). Cells were then grown for 3 days in 10% 
KSR, 1 mmol/L NEAA, 1 mM L-glutamine, and 10−7 mol/L 
dexamethasone (Sigma-Aldrich).
Immunocytochemistry
Cells were fixed with freshly prepared 4% paraform-
aldehyde (PFA; Wako, Richmond, VA, USA) for 30 min, 
Table 1. List of Antibodies
Antibody Company Catalog No.
Oct3/4 R&D Systems AF1759
Nanog Millipore MABD24A4
SSEA4 Millipore FCMAB116P
Tra-1-60 Millipore MAB4360A4
GATA4 Santa Cruz Biotechnology Sc-1237
SOX17 R&D Systems AF1924
FoxA2 R&D Systems AF2400
HNF4a Santa Cruz Biotechnology Sc-6556
AFP Santa Cruz Biotechnology Sc-8399
Human serum albumin Abcam AB2406
Alpha-1 antitrypsin Aviva Systems Biology OABB01837
AGXT Abcam AB178699
UGT1A1 R&D Systems AF6490
ASGPR1 Santa Cruz Biotechnology Sc-52623
CK18 Santa Cruz Biotechnology Sc-6259
CK19 Santa Cruz Biotechnology Sc-6278
CYP3A4 Millipore AB1254
Prox1 Sigma P7124
CEBPa R&D Systems MAB7094
Anti-E-cadherin BD Bioscience 610181
Anti-b-catenin BD Bioscience 610153
Anti-ZO-1 Invitrogen 339100
Anti-CD13 Genetex GTX62507
MCR Santa Cruz Biotechnology Sc-11412
Anti-fibronectin Sigma F6140
Anti-vimentin Sigma V5255
Alexa Fluor 568 Thermo Fisher Scientific A11057
Alexa Fluor 555 Thermo Fisher Scientific A21424
Alexa Fluor 488 Thermo Fisher Scientific A21206
Anti-human IgG (FITC) Abcam AB4220
Anti-human IgG (PE) BD Bioscience 555787
Delivered by Ingenta to: Guest User
IP: 84.2.84.94 On: Tue, 07 Nov 2017 12:06:54
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
2224 SAUER ET AL.
washed with PBS, and permeabilized with 0.5% Triton 
X-100 (Thermo Fisher Scientific) in PBS for 15 min. 
Cells were then blocked with 3% bovine serum albumin 
(BSA; Sigma-Aldrich) in PBS for 30 min, followed by 
incubation with a primary antibody (Table 1) in 1% BSA 
solution at 4°C for 1 h. After extensive washing with 
PBS, cells were incubated with a secondary antibody 
labeled with Alexa Fluor 555 (Invitrogen), Alexa Fluor 
568 (Invitrogen), or Alexa Fluor 488 (Invitrogen) in 1% 
BSA solution at room temperature (RT) for 30 min. Cells 
were washed again, counterstained with 4¢,6-diamidino-
2-phenylindole (DAPI; Sigma-Aldrich), and visualized 
using a fluorescence microscope (Zeiss AxioVert 200M; 
Carl Zeiss Inc., Thornwood, NY, USA).
Real-Time qRT-PCR
RNA was extracted with the Qiagen RNeasy Mini Kit 
(Qiagen, Hilden, Germany) for each individual sample and 
assessed for its purity and concentration with NanoDrop 
2000 spectrophotometer (Thermo Fisher Scientific) and 
reverse transcribed using SuperScript III First-Strand 
synthesis kit (Cat. No. 18080-051; Life Technologies). 
Primers for quantitative gene expression RT-PCR SYBR 
Green assays were designed using primer3 software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) 
to gen erate an amplicon of 60–150 bp that is spread over 
exon junction areas unless it was impossible. Primers 
designed were not to discriminate multiple transcript vari-
ants within given gene and avoided any known sequence 
variability. Assays for several potential reference genes 
were also designed. The sequences of primers along with 
Entrez gene IDs are presented in Table 2.
All real-time PCRs were performed in duplicate for 
each gene. All samples tested with particular assays were 
run on the same plate to avoid plate-to-plate variation. 
An assay for each region was set up as follows: for 10 µl 
of total reaction volume, 5 µl of 2X USB VeriQuest Fast 
SYBR qPCR master mix (Affymetrix, Santa Clara, CA, 
USA, PN 75690), 200 nM of each primer, 4 ng of template 
reverse-transcribed RNA, and water were used. SYBR 
Green assays were run on 7500FAST instrument (Applied 
Biosystems, Thermo Fisher Scientific) in the fast mode 
under conditions recommended by the master mix manu-
facturer, namely, uracil–DNA glycosylase (UDG) treat-
ment at 50°C for 2 min, 95°C for 5 min followed by 40 
cycles of 95°C for 3 s and 60°C for 30 s followed by a 
melt curve stage. Data were analyzed by the 7500FAST 
instrument software v2.0.6 (Applied Biosystems, Thermo 
Fisher Scientific). Assay validations using five 10-fold 
dilutions of cDNA ranging from 40 to 0.004 ng of RNA 
input per reaction showed linear range and detection limit 
of 40 ng to 0.04 ng for all assays tested with PCR efficiency 
98%–110%. Each reaction plate included duplicate wells 
of no template control reactions for each assay. Among 
15 potential reference genes tested, N-acetyltransferase 
1 (NAT1), ubiquilin 1 (UBQLN1), and F-box and WD 
repeat domain containing (FBXW2) were selected as least 
variable. Their mean Ct value was used in data analysis by 
the DCt method. Values of “iPS cells,” “hepatic differen-
tiation, day 3,” and “hepatic differentiation, day 14” repre-
sent the mean of DCt of three independent differentiation 
experiments, using two iPSC lines generated by Sendai 
viral vectors, and one iPSC line generated by episomal 
vectors. Values for “primary human hepatocytes” repre-
sent a single specimen. Relative expression values were 
calculated by the 2−DCt method multiplied by hundred and 
shown in a logarithmic scale.
Detection of the loss of episomal plasmids or Sendai 
virus after reprogramming was carried out according to 
manual instructions of the episomal iPSC reprogramming 
plasmid kit (SBI, No. SC900A-1; System Bioscience, 
Palo Alto, CA, USA) and TaqMan iPSC Sendai detection 
kit (No. A13640; Applied Biosystems).
MicroRNA Expression Profiling
Arrays of DNA oligonucleotides that corresponded 
to the sense sequences of 529 mature human miRNAs 
(Sanger database 2012) with 5¢ amino modifier at C6 
were printed on Corning epoxide slides (Cat. No. 40043; 
Corning, NY, USA) in 3XSSC buffer in a final concen-
tration of 50 nM (50 fmol per spot) in quadruplicates at 
the Albert Einstein College of Medicine as previously 
described (17). The slides were treated before hybridiza-
tion as previously described (2). Small RNA-enriched 
sample (250–500 ng; mirVana kit; No. 1560; Ambion, 
Thermo Fisher Scientific) was used for the target prepara-
tion with some modifications from Goff et al. (7). Briefly, 
poly (A) tailed RNA was submitted to cDNA synthesis 
using dT17 RT primer with 3DNA capture sequence on 
the 5¢ end complimentary to sequence attached to either 
Oyster 550 or Oyster 650 carrying 3DNA dendrimer 
(http://genisphere.com/sites/). Tagged cDNA was com-
bined and concentrated in the Nanosep 10K omega cen-
trifugal device (No. OD010C34; PALL Life Sciences, 
Port Washington, NY, USA). Retrieved volume was 
adjusted to 15 µl, mixed with 2X-SDS-based hybridiza-
tion buffer (No. C600V600S25; Genisphere, Hatfield, 
PA, USA) heated for 10 min at 75°C and applied to arrays 
for hybridization at 50°C overnight. The next day arrays 
were washed and hybridized for 4 h at 64°C with the 
mixture of custom 3DNA (900) Dendrimer Oyster 550/
Oyster 650 signal amplifiers (Cat. Nos. AA9050 and 
AC9060; Genisphere). All further steps were done previ-
ously described (17). Average intensity for each probe was 
computed and then normalized on global median inten-
sity for a particular slide. Values were log2 transformed 
and submitted to hierarchical cluster analysis by Eisen’s 
Gene Cluster 3.0 and Java Treeview software, available 
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for free download from http://softadvice.informer.com/
Open_Source_Cluster_Exe.html and https://sourceforge.
net/projects/jtreeview/, respectively.
Glycogen Content
Cells were fixed in alcoholic formalin (40% formal-
dehyde and 95% ethanol, 1:10 dilution) for 1 h. Periodic 
acid–schiff (PAS) staining was carried out on cells using 
a kit (395B-1KT; Sigma-Aldrich) according to the manu-
facturer’s instructions. Diastase digestion was performed 
to confirm that positive staining was due to the presence 
of glycogen.
Indocyanine Green Staining
Indocyanine green (ICG; MP Biomedicals, Santa Ana, 
CA, USA) was dissolved in DMEM (Lonza) contain-
ing 10% FBS to a final concentration of 1 mg/ml. iHeps 
were incubated with 1 mg/ml ICG at 37°C for 15 min. 
Afterward, cells were washed three times with PBS and 
examined by bright-field microscopy. After the examina-
tion, the dish was refilled with DMEM containing 10% 
FBS, and the cells were examined again 3 h later.
Urea Secretion
The iHeps or primary human hepatocytes (106) were 
cultured in fresh media for 16 h. Urea secretion into 
the media was analyzed using a urea assay kit (Sigma-
Aldrich) according to the manufacturer’s instructions.
Flow Cytometry
iHeps were released with trypsin/EDTA and washed 
with PBS at day 14 of differentiation, and then fixed 
with 4% PFA (Wako) for 30 min. After permeabilization 
with 0.5% Triton X-100 for 15 min, cells were blocked 
with 3% BSA for 30 min. The cells were then incu-
bated with primary antibodies against human- specific 
antibodies (Table 1) for 30 min, followed by incubation 
with a secondary antibody labeled with Alexa Fluor 555 
(Invitrogen) or Alexa Fluor 488 (Invitrogen) for an addi-
tional 30 min. Flow cytometry was performed on an LSR 
II Flow Cytometer (BD Biosciences), and data were ana-
lyzed using the FACS Diva software.
Mouse Transplantation Model
Transgenic mice (PiZ) were originally generated by 
Sifers et al. (20) by inserting into the mouse germline a 
14.4-kb DNA fragment of the human genome containing 
the entire SERPINA1 gene carrying a G-to-A transition 
at nucleotide position 11,940 in exon 5, which leads to 
the expression of a mutant form of a-1 antitrypsin (ATZ) 
with a glutamic acid to lysine substitution at amino acid 
366. Accumulation of the misfolded ATZ protein within 
hepatocytes produces endoplasmic reticulum stress. We 
showed previously that wild-type mouse cells transplanted 
into the livers of the PiZ mice proliferate spontaneously, 
repopulating the host liver by cell competition (4). For 
transplantation of human iHeps, we bred PiZ mice with 
immunodeficient Scid mice, which are homozygous for 
the prkdc gene mutation [National Cancer Institute (NCI), 
Bethesda, MD, USA], Scid/NCr, C.B-Igh-1b/lCr Tac-
Prkdcscid, and backcrossed to generate PiZ/Scid mice. The 
PiZ/Scid mice were maintained at the Animal Institute of 
Albert Einstein College of Medicine. All animal experi-
ments were performed with the approval of the Institutional 
Animal Care and Use Committee (IACUC) of the Albert 
Einstein College of Medicine and were within the guide-
lines for humane care of laboratory animals.
Cell Preparation and Transplantation
On the day of transplantation, iHeps were released from 
the culture dish using trypsin/EDTA and suspended in PBS. 
After counting and determination of viability by trypan 
blue (Gibco) exclusion method, the cells were stored on ice 
for up to 60 min until transplantation. Two 5- to 6-week-
old male PiZ/Scid mice were anesthetized by inhalation 
of a nitrous oxide/oxygen isoflurane gas mixture (Abbott 
Laboratories, Abbott Park, IL, USA). The iHeps were 
transplanted as previously described (4). Briefly, the cau-
dal pole of the spleen was exposed through a left flank inci-
sion, and a ligature was fashioned into a loose knot around 
the caudal pole. One million iHeps were injected into the 
splenic pulp using a syringe with a 27-gauge needle. The 
knot was then tightened, and the incision was closed.
Liver Immunohistochemistry
PiZ/Scid mice were sacrificed 3 months after iHep 
transplantation, and livers were harvested. Liver frag-
ments fixed in 10% formaldehyde (Sigma-Aldrich) were 
washed with 70% alcohol, progressively dehydrated, and 
embedded in paraffin (Sigma-Aldrich). The tissue sec-
tions were dewaxed, rehydrated, and heated in a micro-
wave oven for 3 min in an Antigen Unmasking Solution 
(pH 6.0; Vector Laboratories, Burlingame, CA, USA). 
The sections were treated with 3% H2O2 (Sigma-Aldrich) 
for 10 min at RT before blocking with 10% goat serum 
(Abcam, Cambridge, MA, USA) for 1 h. After this, the 
sections were exposed to primary antibodies (Table 1) 
at 4°C overnight. After intense washing with PBS, the 
sections were exposed to horseradish peroxidase (HRP)-
conjugated secondary antibodies (Millipore) for 2 h at RT. 
Next, 3,3-diaminobenzidine (DAB) Peroxidase Substrate 
Kit (Vector Laboratories) was used to detect HRP second-
ary antibodies according to the manufacturer’s instruc-
tions. Slides were counterstained with hematoxylin 
(Sigma-Aldrich) and dehydrated before application of 
mounting medium (Dako, Carpinteria, CA, USA).
For simultaneous detection of human serum albumin 
(HSA)-containing iHeps and polymerized globules of 
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ATZ, paraffin sections of the recipient PiZ/Scid mouse 
livers were hydrated and blocked with PBS contain-
ing 10% normal donkey serum (Abcam), 0.1% Triton® 
X-100, and 1% BSA for 45 min at RT. The sections 
were then incubated overnight at 4°C with an anti-a-1 
antitrypsin mouse monoclonal antibody (Abcam) and an 
anti-HSA polyclonal antibody (Abcam) at 1:100 dilution. 
The antibody binding was visualized using secondary 
anti-mouse IgG antibodies conjugated with Alexa Fluor 
568 (Life Technologies) and anti-rabbit IgG antibodies 
conjugated with Alexa Fluor 486 (Life Technologies). 
The sections were then covered with a mounting solution 
containing DAPI (Vector Laboratories) for visualization 
of the nuclei.
Human Primary Hepatocytes and Cell Lines
Cryopreserved isolated human hepatocytes were pur-
chased from Triangle Research Labs (TRL; Charlottesville, 
VA, USA). Newborn human foreskin fibroblasts (NuFFs) 
were purchased from Amsbio (Cambridge, MA, USA). 
Cell suspensions were handled and seeded according to 
the manufacturer’s instructions.
Statistical Analysis
SPSS 18.0 software (IBM, Armonk, NY, USA) was 
used for statistical analysis. Values are presented as mean 
with standard deviation (SD). Analysis was performed by 
Student’s t-test. A value of p < 0.05 was considered as sta-
tistically significant.
RESULTS
Isolation and Storage of Human Urinary  
Epithelial Cells
Human urine samples were collected after obtain-
ing informed consent from donors and approval from the 
institutional review board (IRB) of the Albert Einstein 
College of Medicine. The urine donors did not receive any 
financial or material incentive. We collected 250–500 ml 
of freshly voided midstream urine from two individuals. 
Both donors provided five urine samples at different time 
points. After 4 to 6 days of cultivation, one to five colonies 
emerged per well of a six-well plate in at least four of the 
five urine samples from each donor (Fig. 1A). Stable cell 
populations grew in 4 days after first passaging of the cells. 
Consistent with previous reports, the cell colonies showed 
two types of morphologies: one showing a smooth-edged 
contour and the other with a cobble stone-like cell mor-
phology (31). To determine whether the urine sample could 
be stored for transportation before culturing the epithelial 
cells, we kept freshly donated urine on ice for 4 to 48 h 
before isolating and culturing the cells by our standard pro-
cedure. Significantly, cells harvested from urine samples 
stored for 48 h showed an only slightly delayed cell growth 
compared with cells isolated from freshly voided urine or 
urine stored for 4 h (Fig. 1B).
Characterization of Human Urinary Epithelial Cells
To validate the renal origin of the newly generated 
 urinary epithelial cell colonies, and to distinguish the 
Figure 1. Human urinary epithelial cells. (A) Urinary epithelial cells at day 5 and day 10 after isolation. (B) Urinary epithelial cells 
isolated and cultured after 4 and 48 h of storage at 4°C. Scale bars: 200 µm.
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cells with elongated morphology from human fibroblasts, 
we performed immunofluorescence microscopy to detect 
markers of human epithelial cells, fibroblasts, and renal 
tubular epithelial cells (Fig. 2). Neonatal foreskin fibro-
blasts (NuFFs) were used as a control. The urinary epi-
thelial cells displayed a positive staining for the epithelial 
 markers, E-cadherin, b-catenin, and zonula occludens-1 
(ZO-1), whereas fibroblasts were negative for those mark-
ers. The urinary epithelial cells were positive for the fibro-
blast marker fibronectin but showed a much fainter staining 
for another fibroblast marker, vimentin. The urinary epi-
thelial cells were strongly positive for the renal proximal 
tubular marker CD13. The mineralocorticoid receptor 
(MCR), also known as the aldosterone receptor or nuclear 
receptor subfamily 3, group C, member 2 (NR3C2), was 
expressed in urinary cells indicated by positive staining. 
These results confirmed that cells cultured from urine were 
epithelial cells of renal tubular origin.
Integration-Free Generation of iPSCs From 
Urinary Epithelial Cells
We have used two different strategies for reprogram-
ming the urinary epithelial cells of both donors, which 
do not involve integration of the transgenes into the cel-
lular genome. The first method was to infect the urinary 
epithelial cells at passage 2 with recombinant Sendai 
viruses expressing the reprogramming factors hOCT3/4, 
hSSOX2, hKLF4, and hc-MYC. In the second approach, 
we transfected the urinary epithelial cells with a set of 
three oriP/EBNA episomal plasmids (consisting of the 
latent origin of replication, oriP and the nuclear  antigen-1, 
EBNA of the Epstein–Barr virus) that express the repro-
gramming factors OCT4, SOX2, KLF4, L-MYC, LIN28, 
and an shRNA against p53 by nucleofection (Amaxa). 
By each of these approaches, small colonies with iPSC 
morphologies appeared in 3 to 5 weeks, when using 
urinary cells from both donors (Fig. 3A). The colonies 
were picked and expanded on Matrigel-coated dishes 
using mTeSR media without feeder cells. Both methods 
provided satisfactory reprogramming efficiency; how-
ever, the Sendai virus-based method was slightly more 
efficient when comparing urinary cells derived from the 
same donor. Using the Sendai virus method, we obtained 
49 colonies 20 to 25 days after infection. On the basis of 
the initial cell number of 1 million cells, the calculated 
efficiency is 0.0049%. With the episomal plasmids, 35 
days after nucleofection of 1 million urinary epithelial 
FACING COLUMN
Figure 2. Characterization of urinary epithelial cells. Immuno-
staining of urinary epithelial cells for epithelial markers 
(E-cadherin, b-catenin, and ZO-1), fibroblast markers (fibro-
nectin and vimentin), renal epithelial marker CD13, and miner-
alocorticoid receptor MCR. Scale bars: 200 µm.
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cells, we obtained 28 colonies, leading to a calculated 
efficiency of 0.0028%. This difference could be signifi-
cant in cases where only a small number of somatic cells 
are available for reprogramming.
Characterization of the iPSCs
At passage 4, iPSC lines reprogrammed with either 
oriP/EBNA-1 episomal vectors or recombinant Sendai 
viruses were evaluated for the presence of embryonic 
stem cell (ESC)-specific transcription factors, such as 
OCT3/4 and NANOG, and cell surface proteins, such as 
SSEA4 and TRA-1-60. iPSC lines derived by both methods 
exhibited positive immunofluorescence staining for all 
four ESC-specific antigens (Fig. 3B). An iPSC line was 
considered to be stable when it retained its morphologi-
cal characteristics and continued to express undiminished 
levels of OCT3/4, NANOG, SSEA4, and TRA-1-60 after 
at least 16 passages. No differences in staining pattern or 
intensity were found when iPSCs derived from urinary 
epithelial cells were compared with those derived from 
fibroblasts (data not shown). Consistent with the immuno-
fluorescence findings, real-time RT-PCR analysis showed 
a high expression of pluripotency marker genes LIN28A, 
MYC, NANOG, POU5F1 (encoding OCT3/4), and SOX2 
(Fig. 4B). To evaluate the capacity of the iPSCs to dif-
ferentiate into cells belonging to all three germ layers in 
vivo, iPSC lines derived from both Sendai virus and oriP/
EBNA-1 episomal vector-derived iPSCs were injected 
subcutaneously and beneath the renal capsule of NOD/
Scid mice. All iPSC lines gave rise to teratomas contain-
ing cells from all three germ layers, as shown by H&E 
staining of tissue sections (Fig. 3C). All iPSC lines were 
found to be normal by karyotypic analysis (Fig. 3D). 
Using highly sensitive qPCR methods, we have found 
that after more than 16 passages, the episomal plasmid 
sequences and the Sendai viral sequences were undetect-
able in the iPSCs (data not shown).
Efficient Directed Differentiation of Human Urinary 
Epithelial Cell-Derived iPSCs to iHeps
Two iPSC lines from both donors generated by either 
Sendai virus or oriP/EBNA-1 episomal vectors were dif-
ferentiated to iHeps.
Immunocytochemistry and Gene Expression Profiles
One day after treating urinary epithelial cell-derived 
iPSCs with Wnt3a (50 ng/ml), Activin A (100 ng/ml), and 
FGF2 (100 ng/ml), the cell morphology changed markedly 
from the typical iPSC colony structure. During the follow-
ing 2 days, differentiation toward DE was driven further 
by adding knockout serum replacement (KSR) at progres-
sively increasing concentrations. This treatment resulted in 
a marked decline in the expression of pluripotency mark-
ers OCT3/4, NANOG, SSEA4, and TRA-1-60 in 3 days, 
as shown by immunocytochemical staining (Fig. 4A). This 
result was corroborated by gene expression profiles using 
real-time RT-PCR. The pluripotency genes LIN28A, MYC, 
NANOG, POU5F1 (OCT3/4), and SOX2 that are highly 
expressed in iPSCs were downregulated after inducing the 
differentiation to DE (Fig. 4B). Expression of these genes 
was downregulated further during subsequent steps of 
hepatic differentiation.
In parallel with the downregulation of pluripotency 
markers, DE markers SOX17, FOXA2, and GATA4 
increased during these 3 days. The nuclei of 85%–90% of 
the cells at the DE stage (hepatic differentiation, day 3) 
stained positively for all three endodermal markers 
(Fig. 5A). Hepatocyte nuclear factor 4a (HNF4a) was 
expressed at a low level at this stage of hepatic differen-
tiation. Real-time RT-PCR analysis verified the upregula-
tion of SOX17, FOXA2, and GATA4, as well as that of 15 
other genes that are known to be highly expressed in cells 
at day 3 of hepatic differentiation (Fig. 5B).
In the next step, to induce hepatic specification, the 
cells with DE characteristics were treated with HGF at 
100 ng/ml for the next 8 days. Immunocytochemical 
staining of the cells showed that the expression of 
HNF4a was markedly upregulated after HGF exposure 
(Fig. 6A). a-Fetoprotein (AFP), a marker of fetal hepa-
tocytes, was highly expressed at this stage. The cells also 
expressed both cytokeratin 18 (CK18), a cytoskeletal 
protein, and the bile duct epithelial marker cytokeratin 
19 (CK19).
To induce further maturation of the hepatic progenitor-
like cells to cells with hepatocyte-like characteristics, we 
treated the cells with 10−7 mol/L dexamethasone for 3 
additional days. After this period (hepatic differentiation, 
day 14), immunofluorescence staining showed that the cells 
expressed hepatocyte-preferred proteins including HSA, 
asialoglycoprotein receptor 1 (ASGPR1), serine-pyruvate 
aminotransferase (AGXT), CCAAT/enhancer-binding pro-
tein a (CEBPa), cytochrome P450 3A4 (CYP3A4), 
prospero homeobox protein 1 (PROX1), and UDP-glucu 
ronosyltransferase 1-A1 (UGT1A1) (Fig. 6B).
FACING PAGE
Figure 3. Characterization of urinary epithelial cell-derived iPSCs. (A) iPSC colonies observed after reprogramming urinary epithe-
lial cells with Sendai virus or episomal vectors. (B) Immunocytochemical staining of pluripotency markers Oct3/4, Nanog, SSEA4, 
and Tra-1-60 in Sendai virus or episomal vector-derived iPSCs. (C) iPSC lines differentiated into all three germ layers after subcutane-
ous injection into NOD/Scid mice (hematoxylin and eosin staining). Scale bars: 100 µm (A–C). (D) iPSCs exhibited normal karyotype. 
Analysis of iPSC lines generated using recombinant Sendai viruses or OriP episomal plasmid.
Delivered by Ingenta to: Guest User
IP: 84.2.84.94 On: Tue, 07 Nov 2017 12:06:54
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
2234 SAUER ET AL.
Figure 4. Decline of pluripotency markers after directed differentiation of iPSCs toward hepatocytes. (A) Immunofluorescence stain-
ing of pluripotency markers Oct3/4, NANOG, SSEA4, and TRA-1-60 in iPSCs at day 3 of directed differentiation. One representa-
tive experiment out of three is shown. Scale bars: 100 µm. (B) Real-time qRT-PCR analysis of pluripotency markers LIN28A, MYC, 
NANOG, POU5F1 (OCT4), and SOX2 expression in iPSCs and iPSCs at day 3 (DE) and day 14 (iHep) of directed differentiation 
toward hepatocytes. Data are presented as means of three independent experiments. One specimen of primary human hepatocytes 
(PHH) was used for comparison.
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Figure 5. Appearance and decline of DE markers during directed differentiation toward hepatocyte lineage. (A) Immunocytochemistry 
staining of DE markers SOX17, FOXA2, GATA4, and HNF4a in iPSCs at day 3 after hepatic differentiation. One representative 
experiment out of three is shown. Scale bars: 100 µm. (B) Real-time qRT-PCR results of 18 DE markers in iPSCs and iPSCs at day 
3 and day 14 after hepatic differentiation. Data are presented as means of three independent experiments. One specimen of primary 
human hepatocytes (PHH) was used for comparison.
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For broader characterization of the gene expression pro-
file of the cells, we analyzed the expression of 94 genes 
that are expressed in mature primary human hepatocytes 
(PHH) by real-time RT-PCR. At day 14 at hepatic differ-
entiation, cells expressed ASGPR1 and ASGPR2, and the 
ATP-binding cassette subfamily B member 11 (ABCB11/
BSEP) that is located at the canalicular surface of hepa-
tocytes (Fig. 6C). mRNA expression for these genes was 
significantly higher in cells at day 14 in comparison with 
cells at the DE stage (day 3 of hepatic differentiation) but 
lower than that in PHH. Real-time RT-PCR showed in gen-
eral that cytochrome P450 (CYP) family of proteins was 
expressed at a lower level in cells at day 14 than in PHH 
(Fig. 6C). Nonetheless, some CYP genes were upregulated 
at day 14 in comparison with cells at the DE stage of dif-
ferentiation. CYP2C9 expression was comparable to that 
in PHH, whereas CYP3A5 and CYP3A7 were expressed at 
a lower level. Interestingly, CYP3A7 carries out a role in 
fetal livers that is comparable with the function of CYP3A4 
in adult livers. As CYP3A4 expression was very low in 
cells at day 14 of hepatic differentiation and CYP3A7 was 
upregulated, these results suggest the immaturity of the 
iHeps in the context of CYP expression. Expression of 
several genes encoding cytoplasmic proteins was upregu-
lated in the cells at the final step of hepatic differentiation 
(Fig. 6C). Glutathione S-transferase A1 (GSTA1), cytosolic 
dehydroepiandrosterone sulfotransferase (SULT2A1), fatty 
acid-binding protein 1 (FABP1), methionine adenosyl-
transferase I (MAT1A), nicotinamide N-methyltransferase 
(NNMT), and members of UDP-glucuronosyltransferase 
2 family (UGT2B4 and UGT2B10) were all upregulated in 
cells at day 14 of hepatic differentiation compared with the 
cells at day 3. Genes expressing proteins localized at other 
organelles (nucleus, Golgi apparatus, mitochondria, and 
peroxisomes) were variably upregulated (Fig. 6C). CEBPa 
and the nuclear constitutive androstane receptor (CAR) 
were expressed significantly in cells at day 14. The peroxi-
somal enzyme AGXT was also expressed efficiently.
We also investigated the expression of genes encoding 
proteins that are produced and secreted into the blood by 
hepatocytes (Fig. 6C). All genes in this group that were 
tested were upregulated significantly at hepatic differ-
entiation (day 14), compared with cells at the DE stage 
(day 3). These included AHSG, ALB, ALDOB, AMBP, 
ANG, APCS, CFB, CFHR2, CPB2, CRP, FGA, FGB, 
FGG, HGF, Hp, HPX, ITIH1, ITIH2, ITIH3, ITIH4, KNG1, 
ORM1, ORM2, and RBP4. Genes for a-1 antitrypsin-1 
(SERPINA1), apolipoproteins (APO), and the hormone 
angiotensin (AGT) were also expressed at the final step 
of iHep differentiation. At this time point, the iHep mor-
phology was fully developed toward the polygonal mor-
phology of hepatocytes (Fig. 6D).
Numerous microRNAs (miRNAs) show specific 
expression patterns that are specific for both tissue type 
and developmental stage. To elucidate the pattern of 
miRNA changes, expression level changes of 141 miRNAs 
at different time points (day 3, day 11, and day 14) dur-
ing the directed differentiation were selected to generate 
a heatmap (Fig. 7). miR-122 is known to be a hepatocyte-
specific miRNA, which accounts for about 72% of the 
total miRNA in these cells (26). Our results, based on 
three independent experiments, showed that miR-122 is 
expressed at day 11 and day 14 of directed differentia-
tion of the iPSCs toward iHeps. Members of the miR-302 
family (miR-302a, b, c, d, and miR-367) were expressed 
in iPSCs and DE (day 3) but were downregulated at 
later time points (day 11 and day 14). An onco-miRNA 
cluster (miR-106, 17, 18, 19, 20, and 92) is expressed in 
iPSCs. Expression of these miRNAs was downregulated 
during differentiation, but some of these continued to be 
expressed, although at a reduced level.
Functional Analysis of iHeps
After the final step of hepatocyte-directed differentia-
tion, we investigated some hepatocyte-specific functions of 
the iHeps. Periodic acid–Schiff staining proved their ability 
to synthesize and store glycogen (Fig. 8A). The iHeps were 
able to internalize ICG (Fig. 8A) and release it after a few 
hours. The cells produced and secreted urea in the media. 
Urea secretion by iHeps (6.61 ng/µl) approached the level 
observed with primary human hepatocytes (8.07 ng/µl) 
(Fig. 8B).
Flow Cytometric Analysis for Liver-Specific Proteins
To quantify the proportion of iHeps that express 
 liver-specific proteins, the iHeps were released from 
the culture dishes and costained with antibodies against 
HSA, AGXT, UGT1A1, ASGPR1, and CEBPa. Flow 
cytometric analysis showed that a majority of the iHeps 
expressed HSA (84.5%), AGXT (83.1%), UGT1A1 
FACING PAGE
Figure 6. Characteristics of iHeps after directed differentiation toward hepatocyte-like iHeps. (A) Immunofluorescence staining for 
early hepatocyte markers HNF4a, AFP, CK18, and the biliary epithelial marker CK19 at day 11 of directed differentiation toward 
hepatocyte-like cells. Scale bars: 100 µm. (B) Immunofluorescence staining for mature hepatocyte markers, AGXT, albumin (Alb), 
ASGPR1, CEBPa, Cyp P450 3A4 (Cyp3A4), and Prox1 at day 14 of hepatocyte-directed differentiation. One representative experi-
ment out of three is shown. Scale bars: 100 µm. (C) Real-time qRT-PCR results of 94 hepatocyte markers in iPSCs at day 3 (DE) and 
day 14 (iHep) of hepatocyte-directed differentiation. Data are presented as means of three independent experiments. One specimen of 
primary human hepatocytes (PHH) was used as positive control. (D) iPSC morphology at day 14 of hepatocyte-directed differentiation. 
Scale bar: 100 µm.
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(79.5%), and CEBPa (74.2%), while a subset of these 
cells expressed ASGPR1 (45.9%) of the total iHep popu-
lation (Fig. 8C).
Engraftment of iHeps in the Liver of PiZ/Scid Mice
To determine the engraftability of the iHeps in 
mouse liver, in a pilot study we transplanted 1 million 
iHeps by intrasplenic injection into PiZ/Scid and con-
trol Scid mice. Three months after transplantation, liv-
ers were collected and sections were stained with PAS, 
which visualized ATZ globules (Fig. 9A). Liver sections 
were also stained for HSA using a human-specific anti-
albumin antibody. The human albumin-containing cells 
were visualized using the DAB detection system. Several 
small cell clusters dispersed throughout the liver stained 
positively for human albumin in the livers of PiZ/Scid 
recipients (Fig. 9A). In contrast, only few single iHeps 
were observed in Scid control mouse livers, suggesting 
a moderate repopulation efficacy by human iHeps in the 
PiZ/Scid recipients. Double immnofluorescence stain-
ing of paraffinized liver sections for mouse a-1 anti-
trypsin AAT (ATZ) and HSA showed that, as expected, 
the human albumin-positive cells did not contain ATZ 
globules, whereas most host cells did contain the glob-
ules (Fig. 9B).
DISCUSSION
Isolated human hepatocytes are critically needed for 
disease modeling, drug development, and hepatocyte 
transplantation. The universal shortage of donor livers 
poses a major hurdle to all these applications and high-
lights the need for a renewable source of human hepa-
tocytes. Breakthrough studies enabling the generation of 
iPSCs has focused the attention of several laboratories, 
including ours, to differentiating iPSCs to hepatocyte-
like iHeps (18). Of the various somatic cells that have 
been used to generate iPSCs, renal tubular epithelial cells 
shed in the urine are the most noninvasive cell type to 
collect, and therefore these cells could play an important 
role in personalized medicine. However, hepatocyte-
directed differentiation of iPSCs generated from human 
renal tubular epithelial cells had not been characterized in 
FACING COLUMN
Figure 7. miRNA expression profiles during hepatic differ-
entiation of urine-cell derived iPSCs. A heat map of human 
miRNAs that were differentially expressed at various stages of 
hepatic differentiation (day 3, day 11, and day 14) is shown. 
Primary human hepatocytes and iPSCs served as controls. 
Three independent hepatic differentiation experiments are 
depicted. For cluster analysis, normalized signal intensity data 
were converted into log2. Values above 1 (positive in log2 scale) 
are shown in red, below 1 (negative in log2 scale) in green, equal 
to 1 (0 in log2 scale) in black, and absent values in gray.
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Figure 8. Functional analysis of iHeps. (A) Glycogen content of iHeps as shown by PAS staining, with or without diastase treatment, 
and indocyanine green uptake and release by iHeps. Scale bars: 100 µm for all micrographs in (A). (B) Urea secretion by iHeps into 
the media. Data are presented as means of three independent experiments ± SD. *p < 0.05. (C) Representative flow cytometric analysis 
of iHep cells revealed positive staining for albumin, AGXT, ASGPR1, UGT1A1, and CEBPa.
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Figure 9. Immunohistochemical staining of PiZ/Scid mouse liver sections 3 months after iHep transplantation. (A) PiZ/Scid mouse 
(four copies of Piz gene) liver exhibiting mutant human AAT globules (black arrows) stained red after PAS staining. Scid mouse exhib-
iting no such globules after PAS staining. PiZ/Scid mouse presenting clusters of HSA-positive engrafted iHep cells that are devoid 
of AAT globules (red arrows). Livers of Scid mice (without the PiZ gene) lacked AAT globules but showed the engraftment of single 
HSA-stained iHeps (red arrow). (B) Double immunofluorescence staining of the liver section of PiZ/Scid recipient mice for AAT and 
HSA showed that the HSA-positive clusters of the engrafted iHeps did not contain AAT globules. The DAPI-stained nuclei show blue 
fluorescence. Scale bars: 100 µm.
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detail before. While this article was in review, Si-Tayeb 
et al. reported that hepatocyte-like cells derived from 
urinary epithelial cells of patients with autosomal domi-
nant hypercholesterolemia due to a specific mutation of 
proprotein convertase subtilisin/kexin type 9 (PCSK9) 
exhibited reduced PCSK9 secretion and low-density lipo-
protein (LDL) uptake (22), providing another example of 
disease modeling based on iHeps. In this study, in addi-
tion to extensively characterizing the urinary epithelial 
cell-derived iHeps, we tested whether these cells were 
able to engraft in livers after transplantation into a mouse 
model of a-1 antitrypsin deficiency.
Cell colonies obtained after 4–6 days of cultivation 
of urinary epithelial cells could be grown to a stable cell 
population within the next 2 weeks. The positive stain-
ing for the renal epithelial marker CD13 confirmed that 
cells cultured from urine were of renal tubular origin. 
Our finding that urinary epithelial cells could be isolated 
and cultured from urine that was stored for 48 h at 4°C 
would enable urine samples to be transported to a labora-
tory from the site of collection, such as patients’ homes 
or other collection sites. The two reprogramming strat-
egies that we used do not leave any genomic footprint 
and generate iPSC lines with typical pluripotent stem cell 
features (Fig. 3). The method using recombinant Sendai 
viruses is more expensive but also provides higher repro-
gramming efficiency, compared with the method using 
episomal vectors. This difference could be significant 
in cases where only a small number of somatic cells are 
available for reprogramming.
Wnt3a is expressed at a critical stage of human liver 
development (27). In combination with Activin A, it 
enhances the induction of definitive endoderm and sub-
sequent hepatic lineage specification. To improve the 
efficiency of DE generation, we modified our previous 
hepatocyte-directed differentiation protocol (2) by add-
ing 50 ng/ml recombinant human Wnt3a during the first 
2 days of differentiation. This modification enhanced the 
downregulation of pluripotency markers, along with a 
simultaneous increase in the expression of DE  markers 
such as SOX17, FOXA2, and GATA4 (Figs. 4 and 5). 
Nearly all the cells reached the DE stage at this phase 
of differentiation, which could improve the quality of 
iHeps and their quantitative yield at a later time point of 
differentiation. Consistent with previous reports, almost 
no cells expressed HNF4a at this stage (21). This out-
come was expected because HNF4a is highly expressed 
in extraembryonic endodermal cells, but not in visceral 
endoderm, which results from exposure to Activin A. 
HNF4a, a transcription factor that plays a pivotal role in 
liver development by regulating the expression of several 
hepatocyte-preferred genes, was markedly upregulated 
in the cells after exposure to HGF, coinciding with the 
assumption of the polygonal shape that is characteristic 
of hepatocytes. Interestingly, cells at this stage expressed 
both CK18, a cytoskeletal protein characteristic of hepa-
tocytes and CK19, which is a bile duct epithelial marker 
(Fig. 6A). Such dual expression is characteristic of hepatic 
progenitor cells, which give rise to both hepatocytes and 
bile duct epithelial cells.
HSA was strongly expressed in the iHeps. FABP1, 
MAT1A, NNMT, UGT2B4, and UGT2B10 were upregu-
lated in cells at day 14 after hepatic differentiation com-
pared with the DE stage, indicating progressive attainment 
of these essential functions. ALDOB, which plays a 
key role in both glycolysis and gluconeogenesis, was 
expressed substantially in iHeps. AGXT, which expresses 
a peroxisomal enzyme that reduces oxalate production by 
hepatocytes, was also expressed efficiently. The iHeps-
expressed ASGPR1 and ASGPR2, which are located at 
the sinusoidal surface of hepatocytes and mediate the 
endocytosis of asialoglycoproteins from circulation, and 
ABCB11/BSEP, which is located at the canalicular surface 
of hepatocytes and transports bile salts from hepatocytes 
into the bile, were upregulated in iHeps (Fig. 6B and C). 
These results may perhaps indicate a polarization of the 
iHeps and suggest the appearance of important meta-
bolic functions in the iHeps, at least on the mRNA level. 
However, further immunochemistry experiments would 
indicate a polarization of the iHeps. Interestingly, expres-
sion of UGT1A1, which is expressed mostly after birth 
in human liver, was observed in the iHeps. Expression 
of ASGPR1 and UGT1A1 indicates that iHeps are simi-
lar to mature hepatocytes in some respects. On the other 
hand, CYP3A7 carries out a role in fetal livers that is 
comparable with the function of CYP3A4 in adult livers. 
As CYP3A4 expression was very low in the iHeps and 
CYP3A7 was upregulated, our results suggest the persis-
tence of some characteristics of fetal hepatocytes in the 
iHeps in the context of CYP expression. Consistent with 
this, the expression of AFP, which is characteristic of fetal 
hepatocytes, persisted to a significant extent in the iHeps. 
Thus, the iHeps, which are artificially differentiated in 
vitro, exhibit mixed characteristics of fetal and mature 
hepatocytes. Other important gene expressions detected 
by real-time RT-PCR included GSTA1 and SULT2A1. 
These enzymes detoxify drugs and other exogenous sub-
stances, as well as endogenous compounds within the 
liver. Enzymes involved in fatty acid metabolism, methy-
lation reactions, and the glucuronidation pathway were 
also expressed. FABP1, MAT1A, NNMT, and members of 
UDP-glucuronosyltransferase 2 family such as UGT2B4 
and UGT2B10 were upregulated in cells at day 14 after 
hepatic differentiation compared with the cells at day 3, 
which may indicate a progressive attainment of these 
essential functions in the iHeps.
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Spatial and temporal expression patterns of microRNAs 
are important in cell lineage determination. The most 
abundant microRNA in the liver, miR-122, was expressed 
in iHeps at day 11 and day 14 of hepatic differentiation, 
indicating another liver-specific feature of the iHeps (Fig. 
7). miR-122 expression plays a critical role in hepatic 
lipid metabolism and in protecting the liver against 
inflammation, fibrosis, and neoplastic transformation 
(28). Our results suggest that quantification of miR-122 
expression should be a standard assay for evaluation of 
the level of differentiation of iHep cells. Members of the 
miR-302 family (miR-302a, b, c, d, and miR-367) have 
been reported to induce reprogramming to a pluripotent 
state and are considered markers of stemness (11). We 
found that these miRNAs were only expressed in iPSCs 
and the DE stage and declined markedly at later stages 
of differentiation (day 11 and day 14), indicating an exit 
from the stem cell state. Considered together, the gene 
expression profile of the iHeps indicates that in some 
respects these cells approach PHH in terms of maturation, 
whereas in other respects they resemble fetal hepatocytes 
or hepatic progenitor cells.
To determine whether the human iHeps can engraft in 
the mouse liver, we transplanted the iHeps into the livers 
of Scid mice that were transgenic for ATZ gene, which 
is a mutant form of human a-1 antitrypsin (PiZ/Scid) 
by injection into the splenic pulp, from where the cells 
migrate to the liver through the splenic and portal vein. 
As in the case of patients with the ATZ mutation, the PiZ 
mice, which are transgenic for the Z-type mutant human 
SERPINA1 accumulate the misfolded mutant protein in 
hepatocytes, which can polymerize forming ATZ globules 
and cause cellular stress. We have shown previously that 
wild-type primary mouse hepatocytes engrafted in the 
livers of PiZ mice spontaneously repopulate livers of PiZ 
mice (4). In the present study, we used immunodeficient 
PiZ mice to evaluate whether human iHeps can engraft 
and grow in mouse liver. As hepatocytes initially engraft 
as single cells after transplantation via the intrasplenic 
route, appearance of HSA-positive hepatocyte clusters in 
the Piz/Scid mouse recipients indicated both engraftment 
and subsequent proliferation of the human iHeps (Fig. 9). 
As expected, the human HSA-positive hepatocytes did 
not contain the ATZ globules, which was confirmed by 
double immunofluorescence staining.
Our findings may have an impact on future cell trans-
plantation therapies. Directed differentiation of somatic-
derived iPSCs to hepatocyte-like cells could not only 
provide a cell-based platform for pathophysiological stud-
ies and drug discovery but could also serve as a renew-
able source for hepatocyte transplantation. Availability 
of such cells could facilitate hepatocyte transplantation 
as an alternative for organ transplantation for the treat-
ment of some inherited liver diseases. Here we have 
shown that human urinary epithelial cells can be effi-
ciently reprogrammed into authentic iPSCs and then dif-
ferentiated to hepatocyte-like iHeps. Extensive molecular 
and functional characterization of the iHeps reveals that 
they exhibit some characteristics of mature hepatocytes, 
whereas in other respects, they resemble fetal hepatocytes 
or liver progenitor cells. Thus, urine is a readily avail-
able source for generating human hepatocyte-like cells 
that could aid disease modeling, pharmacological testing, 
and, potentially, hepatocyte transplantation-based regen-
erative medicine.
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